Toll Free: 1-888-928-9744

Eddingpharm - Product Pipeline Review - 2014

Published: Nov, 2014 | Pages: 38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Eddingpharm - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Eddingpharm - Product Pipeline Review - 2014', provides an overview of the Eddingpharm's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Eddingpharm's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Eddingpharm including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Eddingpharm's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Eddingpharm's pipeline products

Reasons to buy

- Evaluate Eddingpharm's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Eddingpharm in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Eddingpharm's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Eddingpharm and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Eddingpharm
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Eddingpharm and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Eddingpharm Snapshot 5
Eddingpharm Overview 5
Key Information 5
Key Facts 5
Eddingpharm - Research and Development Overview 6
Key Therapeutic Areas 6
Eddingpharm - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Eddingpharm - Pipeline Products Glance 12
Eddingpharm - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Eddingpharm - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Eddingpharm - Unknown Stage Pipeline Products 15
Unknown Products/Combination Treatment Modalities 15
Eddingpharm - Drug Profiles 16
IMP-321 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
telatinib 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
ALX-0141 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
EDP-317 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ACTB-1010 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ACTB-1011 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ozoralizumab 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Eddingpharm - Pipeline Analysis 26
Eddingpharm - Pipeline Products by Target 26
Eddingpharm - Pipeline Products by Route of Administration 28
Eddingpharm - Pipeline Products by Molecule Type 29
Eddingpharm - Pipeline Products by Mechanism of Action 30
Eddingpharm - Recent Pipeline Updates 32
Eddingpharm - Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38
List of Tables
Eddingpharm, Key Information 5
Eddingpharm, Key Facts 5
Eddingpharm - Pipeline by Indication, 2014 7
Eddingpharm - Pipeline by Stage of Development, 2014 8
Eddingpharm - Monotherapy Products in Pipeline, 2014 9
Eddingpharm - Partnered Products in Pipeline, 2014 10
Eddingpharm - Partnered Products/ Combination Treatment Modalities, 2014 11
Eddingpharm - Phase II, 2014 12
Eddingpharm - Phase I, 2014 13
Eddingpharm - Preclinical, 2014 14
Eddingpharm - Unknown, 2014 15
Eddingpharm - Pipeline by Target, 2014 27
Eddingpharm - Pipeline by Route of Administration, 2014 28
Eddingpharm - Pipeline by Molecule Type, 2014 29
Eddingpharm - Pipeline Products by Mechanism of Action, 2014 31
Eddingpharm - Recent Pipeline Updates, 2014 32
Eddingpharm, Other Locations 36 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify